Annual General Meeting Of Q-Med AB (Publ)

UPPSALA, Sweden, April 29, 2005 (PRIMEZONE) -- The Annual General Meeting of Q-Med AB (publ) was held on April 28, 2005 at 5 p.m. on Q-Med's premises at Fyrisvallsgatan 7, Uppsala.


The meeting decided that a dividend of SEK 8 per share shall be paid, of which SEK 3 comprises the regular dividend and SEK 5 an extra dividend.

Board and fee

The meeting decided, for the period up until the end of the next Annual General Meeting, to re-elect Goran Carstedt, Hakan Edstrom, Mikael Kamras, Anders Milton, Pia Rudengren, Asa Roden and Bengt Agerup as members of the company Board.

At the Board meeting following the Annual General Meeting Goran Carstedt was appointed Chairman of the Board.

Furthermore, the meeting decided that Board fees of SEK 840,000 in total shall be paid for the period 2005/2006, comprising SEK 240,000 to the chairman of the Board and SEK 120,000 to each of the other members of the Board. Bengt Agerup does not receive a Board fee.

A fee shall be paid to the auditors in accordance with reasonable invoicing for the period up until the next Annual General Meeting.

Nominations committee

The Annual General Meeting decided that the nominations committee shall continue to consist of three members and elected Robert Wikholm as chairman (new election), with the assignment of finding, at the latest during the third quarter, two representatives from the major owners to be included in the nominations committee, and that a fee of SEK 60,000 be paid to the committee, to be allocated in accordance with the decision of the committee. This is an unchanged fee compared with the previous year.

Incentives programme in Ixion Biotechnology, Inc. The proposal was approved. It was noted that the meeting expressed the opinion that incentives programs of this kind shall not be used for the remuneration of employees and members of the Board of Q-Med AB for work in subsidiary funds.

 Queries should be addressed to:
 Anne Rhenman, Director Investor Relations and Corporate Communications
 Ph: +46(0) 70-974 90 15.

Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 550 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O-list, Attract 40 Stockholmsborsen.

This information was brought to you by Waymaker

The following files are available for download: